Skip to main content
OpenTrials
Completed

NCT Number: NCT01637116

Profiling Urticaria for the Identification of Subtypes

The primary purpose of this study is to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria.

Additional aims: include the comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Berlin Charité

Berlin, State of Berlin, 10117, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • chronic spontaneous urticaria
  • disease duration > 6 weeks
  • signed and dated informed consent
  • age 18 years or older
  • Non sedating antihistamines may be used on an "on demand" basis throughout the study, in case of high urticaria activity [>50 wheals, and intense pruritus: urticaria activity score (UAS) of 6] or in case of an emergency. Patients may take either cetirizine 10 mg up to a maximum of 4 tablets per 24 hours or fexofenadine 180 mg up to a maximum of 4 tablets per 24 hours. The use of antihistamines and the reason has to be documented by the patient in the patient diary. Patients should avoid the use of antihistamines during the study and especially during the three days prior to skin testing
  • for female with childbearing potential: female will have to use a safe method of contraception to prevent pregnancy and will have to agree to continue this method of contraception during the whole study.

Exclusion criteria

  • intake of immunosuppressives 3 month before Screening Visit and during the course of the study. Immunosuppressives including ciclosporin, methotrexate, mycophenolate, azathioprine and cyclophosphamide need to be stopped at least 3 month before Screening Visit
  • intake of corticosteroids (e.g. oral, injection) 1 month before Screening Visit and during the course of the study. Corticosteroids need to be stopped at least 1 month before the Screening Visit.
  • Previous or present treatment with anti-IgE-antibodies including omalizumab (Xolair)
  • age below 18 years
  • use of tricyclic antidepressants (e.g. amitriptyline), doxepin, leukotriene antagonists (e.g. montelukast, trade name: singulair), H2 antihistamines (e.g. cimetidine, famotidine, ranitidine), sulphasalazine, dapsone, tranexamic acid, warfarin, heparin during the last 4 weeks before the Screening Visit and during the course of the study.
  • pregnancy, lactation or planned pregnancy during the study
  • mentally incapacitated subjects
  • patients protected by the law (adults under guardianship, or hospitalized in a public or private institution for a reason other than the study, or incarcerated)
  • patients suffering from urticaria vasculitis

Treatment and study plan

Primary outcomes

  1. Results of the ASST

    Time frame: 21 days per patient

    to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria

  2. Results of a cell activating assay (BHRA)

    Time frame: 21 days per patient

    to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria

  3. Results of autoantibody-test (anti-IgE and anti-FcRI)

    Time frame: 21 days per patient

    to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria

Secondary outcomes

  1. Results of Urticaria activity score (UAS7)

    Time frame: 21 days per patient

    comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria

  2. Results of HRQoL scores (CU-Q2oL, DLQI)

    Time frame: 21 days per patient

    comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria

  3. Results of laboratory tests (Thyroid antibodies (anti-TPO +/- anti-thyreoglobulin); ANA; Rheumatoid factor; CRP; ESR; total IgE; T3,T4, TSH, diff BB, Helicobacter pylori stool antigen test or breath test; D-Dimer)

    Time frame: 21 days per patient

    comparison of the clinical profiles of autoreactive, autoimmune and non autoreactive / autoimmune urticaria and the quality of life impairment in these subsets of chronic spontaneous urticaria

Sponsors and collaborators

Lead sponsor

Marcus Maurer

Other

Registry information

Acronym: PURIST

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jul 10, 2012
Registry last updated
Jul 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.